Compare NEA & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEA | CRNX |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.9B |
| IPO Year | 2002 | 2018 |
| Metric | NEA | CRNX |
|---|---|---|
| Price | $11.37 | $84.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $76.75 |
| AVG Volume (30 Days) | 776.5K | ★ 2.8M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,039,000.00 |
| Revenue This Year | N/A | $720.10 |
| Revenue Next Year | N/A | $184.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.76 | $28.73 |
| 52 Week High | $11.90 | $84.71 |
| Indicator | NEA | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 46.92 | 90.48 |
| Support Level | $11.17 | $83.47 |
| Resistance Level | $11.68 | N/A |
| Average True Range (ATR) | 0.08 | 0.26 |
| MACD | 0.02 | -1.47 |
| Stochastic Oscillator | 72.22 | 97.58 |
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.